Siddharth Wayangankar, MD
Interventional Cardiology · Jacksonville, FLNPI 1386804565
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Edwards Lifesciences at 49.1% of the total. Reporting peaked in 2019 at $318,011 and has fallen 67.1% since, to $104,503 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,778 payments — averaging $652.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$570K
- Medtronic$405K
- Arrow International, Inc.$65K
- Abiomed$51K
- Abbott$43K
- Penumbra, Inc.$11K
- plus $16K from 33 others
Across 35 payments — averaging $4759.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Essential Medical, Inc.$112K
- Abbott$26K
- W. L. Gore & Associates, Inc.$22K
- Arrow International, Inc.$4K
- Endovascular Engineering Inc.$2K
What the payments were for
- Consulting fees$385,51933%
- Speaking & faculty fees$558,48848%
- Travel & lodging$168,68015%
- Food & beverage$46,7994%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 659 | $569,552 |
| Medtronic(2 entities) | 444 | $404,877 |
| Arrow International, Inc. | 19 | $65,102 |
| Abiomed | 122 | $50,859 |
| Abbott | 243 | $42,570 |
| Penumbra, Inc. | 39 | $10,952 |
| Teleflex LLC | 39 | $9,938 |
| Boston Scientific | 90 | $2,091 |
| Shockwave Medical, Inc | 12 | $415 |
| Cardiovascular Systems Inc. | 8 | $385 |
| Avinger Inc. | 8 | $294 |
| W. L. Gore & Associates, Inc. | 21 | $287 |
| Novartis | 13 | $265 |
| Pfizer | 9 | $176 |
| Angiodynamics, Inc. | 2 | $172 |
| Corindus Inc. | 1 | $163 |
| Endovascular Engineering Inc. | 1 | $158 |
| Contego Medical, Inc | 1 | $149 |
| Surmodics, Inc. | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $120 |
| Johnson & Johnson | 7 | $115 |
| Janssen Scientific Affairs, LLC | 1 | $107 |
| Acist Medical Systems, Inc. | 4 | $105 |
| Amgen | 5 | $86 |
| Bard Peripheral Vascular, Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Cardiva Medical, Inc. | 2 | $41 |
| AstraZeneca | 2 | $39 |
| Bayer | 2 | $39 |
| Merck | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Inspiremd Ltd | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Atricure, Inc. | 1 | $18 |
| Terumo Medical Corporation | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Jenavalve Technology, Inc. | 1 | $6 |
| Cvrx, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$472,332
- CoreValve Evolut$396,226
- MANTA$72,321
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$56,685
- Impella$47,817
- NAVITOR$22,718
- Indigo System$8,970
- SAPIEN 3 Ultra RESILIA$5,307
- Emboshield NAV6 system$5,123
- MitraClip$3,846
- EMBOSHIELD NAV6$3,170
- XIENCE V$3,000
- PASCAL$1,512
- EVOQUE$1,245
- Indigo$1,231
- GUIDELINER$1,096
- COREVALVE EVOLUT R$846
- 3F$569
- ClosureFast$554
- HawkOne$553
How this compares
$1,159,487 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 108 | $1,013 |
| Enoxaparin Sodium | 18 | $583 |
| Atorvastatin Calcium | 24 | $189 |
| Lisinopril | 14 | $76 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Jacksonville
- Dominick AngiolilloJacksonville$387K
- Ruby SatpathyJacksonville$205K
- Bharat GummadiJacksonville$153K
- Raguveer MurthyJacksonville$65K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.